HC Wainwright Begins Coverage on Agios Pharmaceuticals (NASDAQ:AGIO)

HC Wainwright started coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report released on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $58.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 64.70% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank raised their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Finally, Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Stock Up 4.3 %

AGIO opened at $35.22 on Monday. The stock has a market cap of $2.02 billion, a PE ratio of 3.11 and a beta of 0.88. Agios Pharmaceuticals has a twelve month low of $26.66 and a twelve month high of $62.58. The company has a fifty day moving average of $34.29 and a 200-day moving average of $43.03.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Sell-side analysts anticipate that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. State Street Corp raised its stake in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after purchasing an additional 216,484 shares during the period. Vestal Point Capital LP bought a new stake in Agios Pharmaceuticals during the 3rd quarter worth approximately $33,767,000. BNP Paribas Financial Markets grew its position in shares of Agios Pharmaceuticals by 15.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock valued at $531,000 after purchasing an additional 1,570 shares in the last quarter. FMR LLC increased its holdings in shares of Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock worth $2,017,000 after purchasing an additional 33,546 shares during the period. Finally, Intech Investment Management LLC purchased a new position in Agios Pharmaceuticals during the third quarter worth about $892,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.